Only Celebrex is Celebrex: Signed by Pfizer
The old adage has always made us question what's in a name, but Pfizer Canada wants Canadians to think about: what's in a signature? This week, Pfizer Canada is launching a new advertising campaign in support of one of its medications, Celebrex. The Signed by Pfizer campaign focuses on the value of a signature, as a commitment to quality and a symbol of pride in craftsmanship.
"One's signature is a sign of approval; it's a binding contract of authenticity and dependability," says Allen Van der Wee, General Manager, Global Established Pharma Business Unit, Pfizer Canada. "Pfizer is committed to this quality in Celebrex and all its products."
The name Pfizer is now printed on all Celebrex capsules in Canada. This signifies a promise of authenticity, dependability, predictability and quality; the product has been tested and manufactured to the highest of standards.
The ad campaign includes both 30 and 15 second television ads and online ads, featuring a bicycle maker and a fashion designer — two professionals who put much work and attention to detail into their creations before signing their name on the finished product. The analogy illustrates the pride and high standards that Pfizer puts behind its products, and the value of the 'Pfizer' signature.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.